EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects

Panpan Xie iD, Morten T Abildlund, Tine A Bækdal iD, Xuemei He, Yassine K Lyauk iD, Usha Rani H Patted iD, Zu Ning iD, Aixin Shi iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15624 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Panpan Xie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijin…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Hypoglycemic Agents, Blood Glucose. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The trial (NCT04016974) investigated the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide, the first orally administered glucagon‐like peptide‐1 analogue for type 2 diabetes, in healthy Chinese subjects. Materials and Methods This single‐centre, multiple‐dose, placebo‐controlled trial randomized 32 healthy Chinese adults to once‐daily oral semaglutide (3 mg escalating to 14 mg) or placebo for 12 weeks. Blood samples were collected regularly during treatment and follow‐up. The primary endpoint was the area under the semaglutide concentration–time curve over a dosing interval (0‐24 h) at steady state (AUC 0‐24h,sema,SS ). Secondary pharmacokinetic endpoints included the maximum observed semaglutide plasma concentration at steady state (C max,sema,SS ). Supportive secondary pharmacodynamics endpoints included changes in body weight and fasting plasma glucose.

Results

Treatment with all oral semaglutide doses showed dose‐dependent increases in semaglutide exposure in healthy Chinese subjects at steady state, determined by AUC 0‐24h,sema,SS (233, 552 and 1288 h·nmol/L for 3, 7 and 14 mg of oral semaglutide, respectively) and C max,sema,SS . Oral semaglutide treatment was associated with significant reductions in body weight ( p = .0001) and fasting plasma glucose ( p = .0011) versus placebo at the end of treatment. The safety and tolerability of oral semaglutide were consistent with the known profile of glucagon‐like peptide‐1 receptor agonists, with no severe or blood‐glucose–confirmed symptomatic hypoglycaemic events, serious adverse events or deaths. The most frequent adverse events were gastrointestinal disorders.

Conclusions

At steady state, oral semaglutide exposure was dose dependent and close to dose proportionality in healthy Chinese subjects. This is consistent with previous clinical pharmacology results for oral semaglutide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesHypoglycemic AgentsBlood GlucoseHumansMaleDouble-Blind MethodAdultFemaleAdministration, OralChinaYoung AdultDose-Response Relationship, DrugHealthy VolunteersMiddle AgedDiabetes Mellitus, Type 2Area Under CurveBody WeightEast Asian PeopleSemaglutide

Stichwörter der Autor:innen

glucagon‐like peptide‐1 analoguepharmacodynamicspharmacokineticspopulation studyrandomized trialsemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsBlood GlucoseSemaglutide

Autor:innen und Institutionen

  • Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Novo Nordisk Service Centre India Private Ltd, Bangalore, India.
  • Novo Nordisk (China) Pharmaceuticals Co., Ltd, Beijing, China.

ORCID-Profile: Panpan Xie, Tine A Bækdal, Yassine K Lyauk, Usha Rani H Patted, Zu Ning, Aixin Shi

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Xie, P., Abildlund, M. T., Bækdal, T. A., He, X., Lyauk, Y. K., Patted, U. R. H., Ning, Z., & Shi, A. (2024). A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15624

Vancouver

Xie P, Abildlund MT, Bækdal TA, He X, Lyauk YK, Patted URH, et al. A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15624

BibTeX
@article{Xie2024,
  author = {Xie, Panpan and Abildlund, Morten T and Bækdal, Tine A and He, Xuemei and Lyauk, Yassine K and Patted, Usha Rani H and Ning, Zu and Shi, Aixin},
  title = {A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15624}
}
Kostenlos starten →